WALTHAM, Mass., May 8, 2017
/PRNewswire/ -- Alere Inc. (NYSE: ALR) (the "Company")
announced today the successful completion of the previously
announced consent solicitations relating to the Company's 6.500%
Senior Subordinated Notes due 2020, 6.375% Senior Subordinated
Notes due 2023 and 7.250% Senior Notes due 2018 (collectively, the
"Notes").
The Company solicited consents from holders of each series of
Notes to extend the deadline for delivery of certain financial
information and to waive through and until 5:00 p.m., New York
City time, on June 15, 2017
(such time and date, the "Waiver Date"), any default or event of
default that occurred, is continuing or may occur under the
indentures under which the Notes were issued (and its consequences)
in connection with any failure to timely file with the Securities
and Exchange Commission (the "SEC") or to timely furnish to the
relevant trustees pursuant to the indentures, our Annual Report on
Form 10-K for the fiscal year ended December
31, 2016 (the "2016 Form 10-K").
The consent solicitations were made pursuant to the consent
solicitation statement dated as of May 1,
2017, as supplemented by the supplement dated as of
May 4, 2017. As of 5:00 p.m., New York
City time, on May 5, 2017 (the
"Expiration Date"), consents were received from holders in respect
of a majority in aggregate principal amount of the outstanding
Notes of each series for the adoption of the waivers.
The Company has paid or has caused to be paid to each holder who
validly delivered (and did not validly revoke) a consent prior to
the Expiration Date a cash payment equal to $17.50 for each $1,000 principal amount of such holder's
Notes. Any questions regarding these payments should be
directed to the Information and Tabulation Agent, D.F. King & Co., Inc., Attention:
Andrew Beck, at (800) 829-6551 (toll
free) or (212) 269-5550 (banks and brokers) (collect). J.P. Morgan
acted as Solicitation Agent in connection with the consent
solicitations.
This announcement is not an offer to purchase, a solicitation of
an offer to purchase, or a solicitation of consents with respect to
any securities, including the Notes.
About Alere
Alere believes that when diagnosing and
monitoring health conditions,
Knowing now matters™. Alere delivers
reliable and actionable information through rapid diagnostic tests,
resulting in better clinical and economic healthcare outcomes
globally. Headquartered in Waltham,
Mass., Alere focuses on rapid diagnostics for infectious
disease, cardiometabolic disease and toxicology.
Cautionary Statement Regarding Forward-Looking
Statements
This communication contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Readers can identify these statements by
forward-looking words such as "may," "could," "should," "would,"
"intend," "will," "expect," "anticipate," "believe," "estimate,"
"continue," "goal," "budget" or similar words. A number of
important factors could cause actual results of the Company and its
subsidiaries to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to, (i) the risk that the review (the "Review") described
in the Company's (a) Form 12b-25 filed on March 1, 2017 (the "12b-25"), (b) Form 8-K filed
on March 15, 2017 (the "March 8-K")
and (c) Form 8-K filed on April 17, 2017 (the "April 8-K"), is
not completed in a timely manner; (ii) the possibility that the
Review uncovers a misstatement or misstatements in revenue
recognition that are greater than the ranges provided in the
12b-25, the March 8-K or the April 8-K, which may be material in
amount, or uncovers misstatements with respect to other matters;
(iii) the risk that the Review uncovers misstatements that impact
total amount of revenue reported; (iv) the risk that the Review
will uncover circumstances that require additional material
weaknesses in internal control; (v) the risk that these or other
risk factors impact the expected timing of the filing of the 2016
Form 10-K; (vi) the risk that our failure to file the 2016 Form
10-K in a timely manner leads to the acceleration of the maturity
of certain of our indebtedness; and (vii) the risk factors detailed
in Part I, Item 1A, "Risk Factors" of the Company's Annual Report
on Form 10-K for the fiscal year ended December 31, 2015 (as filed
with the SEC on August 8, 2016) and other risk factors identified
herein or from time to time in the Company's periodic filings with
the SEC. Readers should carefully review these risk factors, and
should not place undue reliance on the Company's forward-looking
statements. These forward-looking statements are based on
information, plans, goals, and estimates at the date of this
document. The Company undertakes no obligation to update any
forward-looking statements to reflect changes in underlying
assumptions or factors, new information, future events or other
changes.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/alere-inc-announces-successful-completion-of-consent-solicitations-for-alere-incs-notes-300453494.html
SOURCE Alere Inc.